Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England
MetadataShow full item record
Christensen, H., & Trotter, C. (2017). Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England. Vaccine, 35 (2), 208-211. https://doi.org/10.1016/j.vaccine.2016.11.076
We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive because of declining disease burden. We estimate catch-up vaccination of 1year old children could be cost-effective, incremental on the infant programme with a vaccine price of ⩽£8 per dose. Extending vaccination to 2year olds could only be cost-effective (incremental on infant and 1year old catch-up) with a vaccine price of ⩽£3 per dose and was not cost-effective in sensitivity analyses with more conservative vaccine assumptions. Extending catch-up further to 3-4year olds was not cost-effective. Employing the current criteria for assessing vaccines, our models suggest that even with low vaccine prices only catch-up vaccination in 1year old children could be cost-effective, when considered incrementally on the infant programme.
catch-up, cost-effectiveness, group B, meningococcal disease, vaccination
The research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol in partnership with Public Health England (PHE).
Public Health England (PHE) ()
External DOI: https://doi.org/10.1016/j.vaccine.2016.11.076
This record's URL: https://www.repository.cam.ac.uk/handle/1810/262760
Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International, Attribution-NonCommercial-NoDerivatives 4.0 International